About arrivent biopharma inc - AVBP
Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, licensing, and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company was founded Zheng Bin Yao and Stuart Lutzker on April 14, 2021 and is headquartered in Newtown Square, PA.
AVBP At a Glance
Arrivent BioPharma, Inc.
18 Campus Boulevard
Newtown Square, Pennsylvania 19073
| Phone | 1-628-277-4836 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Other | Net Income | -166,308,000.00 | |
| Sector | Health Technology | Employees | 77 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
AVBP Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.78 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.597 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.00 |
AVBP Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,159,844.156 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
AVBP Liquidity
| Current Ratio | 12.831 |
| Quick Ratio | 12.831 |
| Cash Ratio | 12.057 |
AVBP Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -54.697 |
| Return on Equity | -58.883 |
| Return on Total Capital | -54.13 |
| Return on Invested Capital | -58.881 |
AVBP Capital Structure
| Total Debt to Total Equity | 0.005 |
| Total Debt to Total Capital | 0.005 |
| Total Debt to Total Assets | 0.004 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |